Demographic characteristics of the study cohort by type of transplant
| . | Entire cohort (n = 845) . | Type of HCT . | . | |||
|---|---|---|---|---|---|---|
| . | . | Autologous (n = 417) . | Allogeneic (n = 428) . | |||
| Age (y), median (range) | ||||||
| Age at transplantation | 38.2 (21.0-68.6) | 42.9 (21.0-68.6) | 35.2 (21.1-62.0) | |||
| Age at study participation | 46.3 (23.3-73.0) | 49.1 (23.3-73.0) | 44.5 (24.2-65.5) | |||
| Gender, n (%) | ||||||
| Male | 460 (54.4) | 222 (53.2) | 238 (55.6) | |||
| Race, n (%) | ||||||
| White | 681 (80.6) | 356 (85.4) | 325 (75.9) | |||
| Hispanic | 96 (11.4) | 36 (8.6) | 60 (14.0) | |||
| Other | 68 (8.0) | 25 (6.0) | 43 (10.1) | |||
| Education, n (%) | ||||||
| High school or less | 146 (17.3) | 65 (15.6) | 81 (19.0) | |||
| High school and some college | 314 (37.3) | 142 (34.1) | 172 (40.4) | |||
| College degree | 382 (45.4) | 209 (50.2) | 173 (40.6) | |||
| Household income, n (%) | ||||||
| ≥$60,000/y | 387 (48.4) | 205 (52.0) | 182 (44.9) | |||
| $20,000-59,999/y | 307 (38.4) | 148 (37.6) | 159 (39.3) | |||
| <$20,000/y | 105 (13.1) | 41 (10.4) | 64 (15.8) | |||
| Current health insurance, n (%) | ||||||
| Uninsured | 54 (6.5) | 19 (4.6) | 35 (8.3) | |||
| Duration of follow-up (y), n (%) | ||||||
| 2-5 | 387 (45.8) | 219 (52.5) | 168 (39.3) | |||
| 6-10 | 285 (33.7) | 150 (36.0) | 135 (31.5) | |||
| ≥11 | 173 (20.5) | 48 (11.5) | 125 (29.2) | |||
| Primary diagnosis | ||||||
| Hodgkin's lymphoma | 82 (9.7) | 79 (18.9) | 3 (0.7) | |||
| Non–Hodgkin's lymphoma | 196 (23.2) | 172 (41.2) | 24 (5.6) | |||
| Acute lymphoid leukemia | 52 (6.2) | 8 (1.9) | 44 (10.3) | |||
| Acute myeloid leukemia | 188 (22.2) | 75 (18.0) | 113 (26.4) | |||
| Chronic myeloid leukemia | 223 (26.4) | 22 (5.3) | 201 (47.0) | |||
| Aplastic anemia | 27 (3.2) | 27 (6.3) | ||||
| Other | 77 (9.1) | 61 (14.7) | 16 (3.8) | |||
| Relapse risk at HCT, n (%) | ||||||
| High risk | 322 (38.2) | 194 (46.5) | 128 (30.1) | |||
| Conditioning regimen n (%) | ||||||
| Total body irradiation | 661 (78.5) | 281 (67.9) | 380 (88.8) | |||
| Chronic graft vs host disease | ||||||
| Yes | — | — | 260 (60.9) | |||
| Graft vs host disease prophylaxis/treatment | ||||||
| Cyclosporin A | — | — | 321 (75.0) | |||
| Current health, n (%) | ||||||
| Fair/poor | 173 (20.6) | 73 (17.6) | 100 (23.4) | |||
| Concerns for future health, n (%) | ||||||
| Not concerned | 40 (4.9) | 28 (6.8) | 12 (2.9) | |||
| . | Entire cohort (n = 845) . | Type of HCT . | . | |||
|---|---|---|---|---|---|---|
| . | . | Autologous (n = 417) . | Allogeneic (n = 428) . | |||
| Age (y), median (range) | ||||||
| Age at transplantation | 38.2 (21.0-68.6) | 42.9 (21.0-68.6) | 35.2 (21.1-62.0) | |||
| Age at study participation | 46.3 (23.3-73.0) | 49.1 (23.3-73.0) | 44.5 (24.2-65.5) | |||
| Gender, n (%) | ||||||
| Male | 460 (54.4) | 222 (53.2) | 238 (55.6) | |||
| Race, n (%) | ||||||
| White | 681 (80.6) | 356 (85.4) | 325 (75.9) | |||
| Hispanic | 96 (11.4) | 36 (8.6) | 60 (14.0) | |||
| Other | 68 (8.0) | 25 (6.0) | 43 (10.1) | |||
| Education, n (%) | ||||||
| High school or less | 146 (17.3) | 65 (15.6) | 81 (19.0) | |||
| High school and some college | 314 (37.3) | 142 (34.1) | 172 (40.4) | |||
| College degree | 382 (45.4) | 209 (50.2) | 173 (40.6) | |||
| Household income, n (%) | ||||||
| ≥$60,000/y | 387 (48.4) | 205 (52.0) | 182 (44.9) | |||
| $20,000-59,999/y | 307 (38.4) | 148 (37.6) | 159 (39.3) | |||
| <$20,000/y | 105 (13.1) | 41 (10.4) | 64 (15.8) | |||
| Current health insurance, n (%) | ||||||
| Uninsured | 54 (6.5) | 19 (4.6) | 35 (8.3) | |||
| Duration of follow-up (y), n (%) | ||||||
| 2-5 | 387 (45.8) | 219 (52.5) | 168 (39.3) | |||
| 6-10 | 285 (33.7) | 150 (36.0) | 135 (31.5) | |||
| ≥11 | 173 (20.5) | 48 (11.5) | 125 (29.2) | |||
| Primary diagnosis | ||||||
| Hodgkin's lymphoma | 82 (9.7) | 79 (18.9) | 3 (0.7) | |||
| Non–Hodgkin's lymphoma | 196 (23.2) | 172 (41.2) | 24 (5.6) | |||
| Acute lymphoid leukemia | 52 (6.2) | 8 (1.9) | 44 (10.3) | |||
| Acute myeloid leukemia | 188 (22.2) | 75 (18.0) | 113 (26.4) | |||
| Chronic myeloid leukemia | 223 (26.4) | 22 (5.3) | 201 (47.0) | |||
| Aplastic anemia | 27 (3.2) | 27 (6.3) | ||||
| Other | 77 (9.1) | 61 (14.7) | 16 (3.8) | |||
| Relapse risk at HCT, n (%) | ||||||
| High risk | 322 (38.2) | 194 (46.5) | 128 (30.1) | |||
| Conditioning regimen n (%) | ||||||
| Total body irradiation | 661 (78.5) | 281 (67.9) | 380 (88.8) | |||
| Chronic graft vs host disease | ||||||
| Yes | — | — | 260 (60.9) | |||
| Graft vs host disease prophylaxis/treatment | ||||||
| Cyclosporin A | — | — | 321 (75.0) | |||
| Current health, n (%) | ||||||
| Fair/poor | 173 (20.6) | 73 (17.6) | 100 (23.4) | |||
| Concerns for future health, n (%) | ||||||
| Not concerned | 40 (4.9) | 28 (6.8) | 12 (2.9) | |||